Navigation Links
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Date:1/13/2009

ucts that address patient need, which are first-in-class and focus on specialty pharmaceutical markets."

"Today's option agreement is an outstanding corporate achievement for Ception that satisfies our fund raising requirements and provides an excellent partner to advance our novel development programs faster and with greater global reach," said Stephen Tullman, president and CEO, Ception Therapeutics. "Based on our shared experience, commitment, and management philosophies, I have very high expectations that this collaboration will be a win-win for both companies and the patients whom we will serve."

About Reslizumab and Eosinophilic Esophagitis

Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). IL-5 plays a crucial role in the maturation, growth and chemotaxis of eosinophils, inflammatory cells implicated in a number of allergic diseases. Granted orphan drug status for pediatric eosinophilic esophagitis by the U.S. Food and Drug Administration, reslizumab currently is being evaluated in a large multi-center Phase IIb/III study.

Eosinophilic esophagitis (EE) is a disease that has become increasingly recognized in children and adults over the last decade. IL-5 is the major cytokine responsible for the eosinophilic inflammation of the esophagus seen in EE. The disease is characterized by an accumulation of eosinophils in the esophagus in association with symptoms that frequently mimic severe gastro-esophageal reflux disease (GERD). Specifically, patients typically report symptoms that include difficulty feeding and failure to thrive in younger children, as well as vomiting, epigastric or chest pain, dysphagia, and food impaction. There are no approved pharmacologic therapies specifically for EE, although corticosteroids sometimes are administered to patients.

About Cephalon, Inc.

Founded in 1987, Cephalon,
'/>"/>

SOURCE Cephalon, Inc.; Ception Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
9. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
10. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Hill Studios, in partnership with the UCSF School of ... therapy games that have been specifically designed to help ... disease. Sue Lifschiz, a woman with Parkinson,s, will demonstrate ... levels to meet the needs of a variety of ...
... May 16, 2011 New Jersey Center for Prostate ... the nation to treat advanced prostate cancer patients with ... known as autologous cellular immunotherapies.  PROVENGE was approved by ... treatment of men with asymptomatic or minimally symptomatic metastatic ...
Cached Medicine Technology:Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference 2Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference 3New Jersey Center for Prostate Cancer & Urology Among First in Nation to Treat Advanced Prostate Cancer Patients with PROVENGE 2
(Date:7/11/2014)... July 11, 2014 The report ... Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive ... Global Trends & Forecasts to 2019 ” defines ... analysis and forecasting of the market value of ... the driving and restraining factors for the global ...
(Date:7/11/2014)... 11, 2014 Biostimulants are widely applied ... turf and ornamentals. These also help turf and ornamentals ... of roots. Turf, ornamentals, and flowers appear healthy and ... usage has increased from the last few years. The ... ornamentals is Europe, with around 40% share in 2013, ...
(Date:7/11/2014)... 10, 2014) Obese and overweight firefighters are ... care providers, according to new research from The ... (UTHealth). , National guidelines state that health care ... of maintaining a healthy weight. Firefighters have high ... leading cause of line-of-duty deaths in firefighters. This ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... July 11, 2014 Riverside Health System became ... (CBCC) in Virginia in late 2012 and now, in partnership ... to residents throughout the Williamsburg and Newport News region. , ... services and benefits to independent older adults who wish to ... a safety net of continuing care services as well as ...
Breaking Medicine News(10 mins):Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... kind, an expert group in the US advises against routine ... mutations in the BRCA1 and BRCA2 genes increase the risk ... Services Task Force now says that routine screening for the ... first time the group has made a decision on genetic ...
... While nutritional status has improved worldwide over the ... emerged A global nutrition transition has and is ... and // poor nutritional status continue to exist, ... significant public health issues globally. A demographic shift ...
... tea contains chemicals that seem to be effective in ... at the University of South Florida have found that ... in the brains of mice genetically programmed to develop ... is a major antioxidant in green tea and has ...
... has lead to approval of FDA for new generic version ... from other countries. ,Zidovudine (AZT), is an anti-retroviral ... prevents the replication of the virus inside the humans by ... used in combination with other anti-retroviral drugs to combat HIV ...
... Ezhutthellam AADHI Bhagawan Mudattre Ulagu”,Wondering what the above verses ... is doing in this special report about nanotechnology? // ... Kurral” – Ouvvay,Such is the ingenuity of its author, ... the branches of knowledge, as if he had hollowed ...
... and Chinese Biotech Company join hands to form a ... ,The Japanese company GNI merged with Chinese company ... would be done by Shanghai Genomics. China will be ... new compounds for lung fibrosis and lung injury, such ...
Cached Medicine News:Health News:Scientists Consider About New Technology Called Nanotechnology 2
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Medicine Products: